Guidant files suit against J&J to complete merger

Share this article:
Guidant filed a federal lawsuit yesterday to force Johnson & Johnson to complete its $25.4 billion acquisition of the company, The New York Times reports.
J&J contends the deal is now void because of Guidant's financial and legal problems.
Guidant, based in Indianapolis, disclosed yesterday that the Securities and Exchange Commission has opened a formal investigation into the timing of company disclosures about problem heart devices and trading in company stock. The company is already under investigation by the FDA and the Justice Department in connection with its handling of product safety issues.
The merger agreement, unless salvaged, would be one of the biggest ever to collapse because an acquiring company maintained that its target's value had fallen materially before the deal closed, the assertion J&J has made and Guidant has rejected, The Times reported.
In a statement, J&J said it planned on fighting Guidant's lawsuit, filed in U.S. District Court in Manhattan.
J&J has taken the position that Guidant's problems have affected its long-term outlook. Guidant has described any affect as short term.
Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?